Wintermute Biomedical Inc.

Wintermute Biomedical is a research-led biopharmaceutical company headquartered in Melbourne, Australia, with operations in the United States. The company specializes in the development of next-generation antimicrobial therapies by utilizing a patented platform that enables the aqueous formulation of medium- and long-chain fatty acids. Their primary therapeutic candidate is Solexan, an investigational topical treatment designed to address shingles and associated pain by leveraging the antimicrobial properties of undecylenic acid. The company differentiates its approach by focusing on evidence-driven clinical research, seeking to translate academic and medical findings into effective, clinically tested treatments for infectious diseases and antimicrobial resistance.

This work addresses significant unmet clinical needs for patients suffering from conditions such as shingles, which affects approximately one million people annually in the United States. By advancing Solexan through clinical trials, including the ZOSTER EASE Phase Ib study, Wintermute Biomedical aims to provide a more targeted therapy compared to currently available standard treatments. The company collaborates with clinical partners and academic institutions to conduct rigorous, patient-centered trials that evaluate safety, tolerability, and healing efficacy. These efforts are supported by private investment, including a successful 1.3 million USD funding round, and the company continues to expand its board and strategic leadership to progress its pipeline of novel antimicrobial formulations.